S
Sébastien Bonnet
Researcher at Laval University
Publications - 195
Citations - 12429
Sébastien Bonnet is an academic researcher from Laval University. The author has contributed to research in topics: Pulmonary hypertension & Medicine. The author has an hindex of 54, co-authored 171 publications receiving 10254 citations. Previous affiliations of Sébastien Bonnet include University of Alberta & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension: Mechanistic and Therapeutic Implications.
Kuang-Hueih Chen,Asish Dasgupta,Jianhui Lin,François Potus,Sébastien Bonnet,James Iremonger,Jennifer Fu,Jeffrey Mewburn,Danchen Wu,Kimberly J. Dunham-Snary,Anne L. Theilmann,Zhi-Cheng Jing,Charles C.T. Hindmarch,Mark L. Ormiston,Allan Lawrie,Stephen L. Archer +15 more
TL;DR: In this article, the fission mediator dynamin-related protein 1 (Drp1) must be replaced by dynamin related protein 1 in pulmonary arterial hypertension (PAH), a hyperproliferative, apoptosis resistant disease.
Journal ArticleDOI
Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension
Diederik E. van der Feen,Kondababu Kurakula,Eve Tremblay,Olivier Boucherat,Guido P. L. Bossers,Robert Szulcek,Alice Bourgeois,Marie-Claude Lampron,Karima Habbout,Sandra Martineau,Roxane Paulin,Ewelina Kulikowski,Ravi Jahagirdar,Ingrid Schalij,Harm Jan Bogaard,Beatrijs Bartelds,Beatrijs Bartelds,Steeve Provencher,Rolf M. F. Berger,Sébastien Bonnet,Marie-José Goumans +20 more
TL;DR: RVX208, a clinically available BET-inhibitor, modulates pro-proliferative, pro-survival and pro-inflammatory pathways, potentially through interactions with FoxM1 and PLK1, proteins implicated in the DNA damage response.
Journal ArticleDOI
DNA Damage and Pulmonary Hypertension.
Benoit Ranchoux,Jolyane Meloche,Roxane Paulin,Olivier Boucherat,Steeve Provencher,Sébastien Bonnet +5 more
TL;DR: Recent evidence of DNA damage and DNA repair deficiency and their implication in PAH pathogenesis is provided to provide an overview of recent evidence.
Journal ArticleDOI
Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension.
Junichi Omura,Karima Habbout,Tsukasa Shimauchi,Wen-Hui Wu,Sandra Breuils-Bonnet,Eve Tremblay,Sandra Martineau,Valérie Nadeau,Kassandra Gagnon,Florence Mazoyer,Jean Perron,François Potus,Jianhui Lin,Hamza Zafar,Hamza Zafar,David G. Kiely,David G. Kiely,Allan Lawrie,Stephen L. Archer,Roxane Paulin,Steeve Provencher,Olivier Boucherat,Sébastien Bonnet +22 more
TL;DR: It is demonstrated that H19 is upregulated in decompensated RV from PAH patients and correlates with RV hypertrophy and fibrosis, and circulating H19 levels in plasma discriminatePAH patients from controls, correlate with RV function and predict long-term survival in 2 independent idiopathic PAH cohorts.
Journal ArticleDOI
Potassium channel diversity in the pulmonary arteries and pulmonary veins: implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension.
TL;DR: This review describes the ionic heterogeneity manifest in the pulmonary circulation, particularly as it pertains to hypoxic pulmonary vasoconstriction (HPV) and pulmonary arterial hypertension (PAH), and proposes therapies that locally increase K(+) channel current and expression to treat PHT.